Evidence map›Paper›PMID 39623788›Full record

ReviewEuropean journal of immunology2025

Function and Spatial Organization of Tumor-Invasive Human γδ T Cells-What Do We Know?

Kilian Wistuba-Hamprecht, Hans-Heinrich Oberg, Daniela Wesch

Abstract readReview
In one paragraph

Review in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kilian Wistuba-HamprechtSkin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hans-Heinrich ObergInstitute of Immunology, University Medical Center Schleswig-Holstein and Christian-Albrechts University of Kiel, Kiel, Germany.
Daniela WeschInstitute of Immunology, University Medical Center Schleswig-Holstein and Christian-Albrechts University of Kiel, Kiel, Germany.

Funding

Deutsche Forschungsgemeinschaft WE 3559/6-2Deutsche Forschungsgemeinschaft WI 5021/2-2
6 · The paper itself

Abstract

Human gammadelta (γδ) T cells not only infiltrate or reside in healthy tissues but also enter solid cancers. A large body of evidence suggests that γδ T cells can exert potent anti-tumor effects, although conflicting or unfavorable effects have been reported in some cancer entities. Infiltration patterns are key to understanding the complexity of the tumor microenvironment (TME) and its interplay with γδ T cells. The limited data available describe different γδ T cell subsets that are located in different areas around and within tumors. Tumor-infiltrating γδ lymphocytes (γδ TIL) exert cytotoxicity, for example, via the CD95- or TRAIL-axis, produce high amounts of granzymes, and after their activation, tumor necrosis factor (TNF)-α or IFN-γ and express immune checkpoint receptors. Under certain conditions, γδ T cell subsets can express low amounts of IL-17 and seem to contribute to immune regulation/suppression. A polarization of γδ T cells can be influenced by the TME. Inflammatory cytokines, growth factors, or tumor promoters can suppress γδ T cell functionality or even push them toward tumor promotion. To avoid this and to exploit the unique features of γδ T cell-mediated anti-cancer and immune-orchestrating capabilities in future immune therapy approaches, a growing body of preclinical but also clinical studies can be observed.

Indexed as

Intraepithelial LymphocytesLymphocytes, Tumor-InfiltratingNeoplasmsReceptors, Antigen, T-Cell, gamma-deltaT-Lymphocyte SubsetsTumor MicroenvironmentAnimalsHumansReceptors, Antigen, T-Cell, gamma-deltacancer immunotherapycheckpoint inhibitorstumortumor‐infiltrating gammadelta T cellstumor microenvironment

Identifiers

PMID39623788
PMCPMC11739682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.